Supernus Pharmaceuticals | SUPN - Gross Profit On Sales


Supernus Pharmaceuticals reported $160.06M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Abbott USD 6.65B 787M Jun/2026
ANI Pharmaceuticals USD 143.88M 19.7M Mar/2026
Aurora Cannabis CAD 29.79M 16.83M Mar/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Canopy Growth CAD 8.26M 13.2M Mar/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 252.09M 90.07M Jun/2026
Eisai JPY 183.24B 29.83B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pacira USD 133.91M 7.27M Jun/2026
Perrigo USD 313.9M 11.6M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Supernus Pharmaceuticals USD 160.06M 30.7M Jun/2026
United Therapeutics USD 683.8M 35.7M Jun/2026
Xeris Pharmaceuticals USD 72.55M 404K Mar/2026